Pain Management denials at external review

• among the highest

  At 79.5%, this is the 3rd highest overturn rate of the 22 treatment classes with enough decisions to publish one. Reviewers sustained the plan in the remaining 20.5% of disputes.

• the question matters

  The outcome turns on which question was put to the reviewer: 89.6% on medical necessity (n=694) against 50.6% on experimental/investigational (n=243) — a gap of 39 points inside the same treatment class.

• rising

  It has risen over the published record: 9.1% in 2014 against 78.6% in 2025. What drove that is not in this data — the file holds outcomes, not who chose to appeal or how plans changed their own review.

• most-cited standard

  Reviewers named FDA more than any other standard here — 35 decisions, which came out at 40.0%, 39 points below the class as a whole. Citing a standard and the outcome share a cause; this is not the effect of naming it.

California requires each published decision to carry “a detailed case summary that includes the specific standards, criteria, and medical and scientific evidence, if any, that led to the case decision” (Health & Safety Code § 1374.33(h)(1)(K)). These are the elements our extraction found in this class, split by how the decision came out.

Read as description, not instruction. These are patterns in what reviewers wrote, not steps to follow, and no combination of them predicts an outcome. Only codes that cleared the validation gate appear — thirteen did not.

• FDA40.0%35
• American Headache Society—4
• Cochrane—4
• American Academy of Orthopaedic Surgeons—3
• American Academy of Neurology—1

A rate here is the outcome of decisions that named the authority, not the effect of naming it. Reviewers cite the standard they applied; the citation and the outcome share a cause.

• Orthopedic & musculoskeletal80.4%823
• CNS & neuromuscular75.0%88
• Immune disorders—10
• Foot—3
• Genitourinary & kidney—3
• Mental health—2
• Post-surgical complications—2
• Blood disorders—1

Browse all condition classes · Pick your own pair

• Osteoarthritis94.6%410
• Back Pain55.6%153
• Knee Problem/Pain90.8%152
• Vertebral Disc Prob47.6%42
• Other53.1%32
• Migraine80.6%31
• Headache—18
• Neck Problem/Pain—17

• Medical Necessity89.6%694
• Experimental/Investigational50.6%243

Medical-necessity review asks whether the care is needed. Experimental/investigational review asks whether it is likely to be more beneficial than standard therapy — a harder statutory test, and the rates show it.